Clone | Isotype | Applications | Source |
---|---|---|---|
FGK4.5 | Rat IgG2a | - In vivo CD40 activation - B cell stimulation | Bio X Cell |
1C10 | Rat IgG2a | Neutralization studies | R&D Systems |
3/23 | - | Detects CD40 on dendritic cells | PMC |
The FGK4.5 clone demonstrates agonistic activity, enhancing APC activation and anti-tumor responses . Neutralizing antibodies like 1C10 inhibit CD40-CD40L interactions .
Genetic deletion models reveal CD40's roles in:
Atherosclerosis: T cell-specific CD40L deletion reduces plaque formation by 42% (p<0.01)
Viral immunity: CD40-/- mice show:
Tumor immunology: CD40 stimulation on renal carcinoma cells:
CD40 engagement triggers:
TNFR-associated factor (TRAF) recruitment
NF-κB and MAPK pathway activation
Humanized CD40 models show conserved expression patterns but distinct therapeutic responses:
CD40 is composed of an extracellular domain, a transmembrane domain, and a cytoplasmic tail. The extracellular domain is responsible for binding to CD40L, which is expressed on activated T cells and platelets . The interaction between CD40 and CD40L plays a crucial role in the activation of both innate and adaptive immune responses .
The CD40/CD40L interaction is essential for various immune functions, including:
Recombinant CD40 (Mouse) is a laboratory-produced version of the mouse CD40 protein. It is typically expressed in Chinese Hamster Ovary (CHO) cells to ensure proper folding and post-translational modifications . The recombinant protein is used in various research applications to study the CD40/CD40L interaction and its effects on immune responses.
Recombinant CD40 (Mouse) is widely used in immunological research to: